Amgen Inc. (NASDAQ:AMGN) Enjoys Robust Institutional Support with 81% Ownership
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 12 2025
0mins
Source: Yahoo Finance
Institutional Influence: Institutions hold approximately 81% of Amgen's shares, indicating significant influence over the company's share price and decision-making, with the top 18 shareholders controlling 50% of the ownership.
Insider Ownership and Public Stake: Insiders own less than 1% of Amgen, while the general public holds a 19% stake, suggesting that while institutional investors dominate, retail investors can still impact company policies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AMGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AMGN
Wall Street analysts forecast AMGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMGN is 345.87 USD with a low forecast of 272.00 USD and a high forecast of 425.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
11 Buy
7 Hold
1 Sell
Moderate Buy
Current: 342.940
Low
272.00
Averages
345.87
High
425.00
Current: 342.940
Low
272.00
Averages
345.87
High
425.00
About AMGN
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Amgen and Kyowa Kirin Terminate Rocatinlimab Collaboration
- Collaboration Termination: Amgen and Kyowa Kirin announced the termination of their rocatinlimab development and commercialization collaboration on Friday, with Kyowa regaining control over the global program, including regulatory filings and future commercialization, reflecting Amgen's strategic portfolio prioritization.
- Financial Context: In June 2021, Amgen paid a $400 million upfront fee and committed to milestone payments of up to $850 million to Kyowa, indicating initial confidence in the project; however, the current decision suggests a shift in market outlook.
- Clinical Trial Results: To date, the incidence of gastrointestinal ulceration events with rocatinlimab in the ROCKET program is less than 1 per 100 patient-years, yet analysts highlight that the drug's toxicity profile could pose commercial challenges in treating chronic conditions like atopic dermatitis.
- Market Reaction: Amgen's stock fell 0.81% to $340.17 on Friday, with analysts suggesting that the termination of this collaboration will not impact investor sentiment towards Amgen, particularly given the low expectations for therapies targeting the OX40 pathway.
Continue Reading
Eli Lilly Reaches $950 Billion Market Cap as GLP-1 Drug Leader
- Market Leadership: Eli Lilly has become the world's most valuable healthcare company with a market cap of approximately $950 billion, having seen its stock price soar 400% over the past five years, primarily driven by the popularity of its GLP-1 drugs, Mounjaro and Zepbound, indicating strong market demand and growth potential.
- New Drug Development Outlook: Amgen is developing a GLP-1 drug called MariTide, which offers a once-monthly injection treatment option that may appeal to patients preferring reduced injection frequency, thereby expanding its market share.
- Clinical Trial Results: In clinical trials, MariTide has demonstrated the ability to help patients lose up to 20% of their body weight over a 52-week period, comparable to existing GLP-1 treatments, highlighting its competitive edge in the weight loss market.
- Investment Value Analysis: Amgen's stock currently trades at a forward P/E ratio of 16, significantly lower than Eli Lilly's 32, indicating its relative undervaluation; if MariTide gains approval, the stock price could see substantial upside, making it an attractive investment opportunity.
Continue Reading